Back to top
more

The Joint (JYNT)

(Delayed Data from NSDQ)

$14.00 USD

14.00
34,777

-0.29 (-2.03%)

Updated Jul 19, 2024 04:00 PM ET

After-Market: $14.07 +0.07 (0.50%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value A Growth F Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 38% (96 out of 250)

Industry: Medical - HMOs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Valneva (VALN) Gets EC's Approval on Chikungunya Vaccine

by Zacks Equity Research

Valneva (VALN) gets European Commission???s marketing authorization in Europe for Valneva???s single-dose Chikungunya vaccine, IXCHIQ. The company is set to launch IXCHIQ in Europe in late 2024.

Henry Schein (HSIC) Banks on Strategic Buyouts Amid Macro Issues

by Zacks Equity Research

Henry Schein's (HSIC) revenue growth is supported by niche acquisitions and partnerships.

Alcon (ALC) Inks Buyout Deal to Expand Its Glaucoma Portfolio

by Zacks Equity Research

Alcon (ALC) announces the closing of its deal to acquire BELKIN Vision. Per the terms of the agreement, Alcon will have access to BELKIN Vision's Direct Selective Laser Trabeculoplasty technology.

Microbot (MBOT) Inks a New Agreement to Begin Trial on LIBERTY

by Zacks Equity Research

Microbot (MBOT) signs a clinical trial agreement with the Baptist Hospital of Miami for its LIBERTY Endovascular Robotic Surgical System as a part of its Investigational Device Exemption.

Quest Diagnostics (DGX) to Expand in Canada With LifeLabs Buyout

by Zacks Equity Research

By integrating LifeLabs into its operations, Quest Diagnostics (DGX) aims to enhance the accessibility and quality of diagnostic services for Canadians.

Bruker (BRKR) Expands in NMR Spectrometry With New FMP Collab

by Zacks Equity Research

Bruker (BRKR) completes the installation of its 1.2 (GHz) Avance nuclear magnetic resonance (NMR) spectrometer at the Leibniz Forschungsinstitut f??r Molekulare Pharmakologie in Berlin.

Neuronetics (STIM) Expands NeuroStar Portfolio With New Launch

by Zacks Equity Research

Neuronetics (STIM) announces the nationwide launch of the Better Me Provider (BMP) program developed in collaboration with TMS medical experts. The BMP program will be part of the company's NeuroStar product line.

National Vision (EYE) Gains Market Share Despite Macro Woes

by Zacks Equity Research

National Vision (EYE) continues to execute core growth initiatives and further invest in strengthening competitive advantages.

Thermo Fisher (TMO) Expands Central Lab Footprint in Kentucky

by Zacks Equity Research

Thermo Fisher (TMO) announces expansion of its central laboratory operations in Kentucky. The new space in Covington will be in addition to its existing central lab in Highland Heights.

Neogen (NEOG) Expands in Food Safety With Petrifilm Feeder Launch

by Zacks Equity Research

Neogen (NEOG) launches Petrifilm Automated Feeder, which allows automatic feeding and enumeration of up to 300 petrifilm plates in 33 minutes. The system improves the efficiency of food safety testing labs.

Quest Diagnostics (DGX) Inks Deal to Acquire Allina Health

by Zacks Equity Research

Quest Diagnostics (DGX) signs an agreement to acquire Allina Health's select laboratory assets. The deal is aimed at expanding Quest Diagnostics' laboratory services across Minnesota and western Wisconsin.

Charles River (CRL) Inks CDMO Deal With Gates Institutes

by Zacks Equity Research

Charles River (CRL) signs a lentiviral vector contract development and manufacturing organization agreement with Gates Institute to help develop chimeric antigen receptor (CAR) T-cell therapies.

Asensus Surgical (ASXC) Announces New Hospital Tie-Up on Senhance

by Zacks Equity Research

Asensus Surgical (ASXC) announces an agreement with St. Marianna University School of Medicine Yokohama City Seibu Hospital to lease its Senhance Surgical System.

Alcon (ALC) Achieves FDA 510(k) Clearance for Unity VCS and Unity CS

by Zacks Equity Research

Alcon (ALC) gets FDA 510(k) clearance for its Unity VCS and Unity CS. The company will start a thorough program to get real-world feedback before the systems' commercial launch in 2025.

Inspira (IINN) Unveils Business Targets for 2024-25

by Zacks Equity Research

Inspira (IINN) discloses business goals for 2024-25 with the rapid promotion of INSPIRA ART100 and the development of INSPIRA ART (Gen 2).

Thermo Fisher (TMO) Unveils New Research Laboratory in WI

by Zacks Equity Research

Thermo Fisher (TMO) announces a new 72,500-square-foot clinical research laboratory building at its good manufacturing practices lab in Middleton, WI

Haemonetics (HAE) Expands VASCADE Line With New Limited Launch

by Zacks Equity Research

Haemonetics (HAE) expands its VASCADE portfolio with the limited market release of VASCADE MVP XL vascular closure device.

The Joint Corp. (JYNT) Beats Q1 Earnings and Revenue Estimates

by Zacks Equity Research

The Joint (JYNT) delivered earnings and revenue surprises of 300% and 1.91%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

The Joint Corp. (JYNT) Upgraded to Buy: What Does It Mean for the Stock?

by Zacks Equity Research

The Joint Corp. (JYNT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

The Joint Corp. (JYNT) Moves 10.1% Higher: Will This Strength Last?

by Zacks Equity Research

The Joint Corp. (JYNT) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

The Joint (JYNT) Rises 30% as Q4 Earnings Beat on Higher Clinics

by Zacks Equity Research

The Joint (JYNT) expects 2024 system-wide sales to be within $530-$545 million.

The Joint Corp. (JYNT) Q4 Earnings and Revenues Top Estimates

by Zacks Equity Research

The Joint Corp. (JYNT) delivered earnings and revenue surprises of 133.33% and 3.34%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

The Joint (JYNT) to Report Q4 Earnings: Here Are the Key Drivers

by Zacks Equity Research

The Joint's (JYNT) fourth-quarter 2023 results are likely to reflect higher expenses and patient volumes.

Select Medical (SEM) Tops Q4 Earnings and Revenue Estimates

by Zacks Equity Research

Select Medical (SEM) delivered earnings and revenue surprises of 16.13% and 3.02%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Is Cigna (CI) Nearing a Medicare Advantage Divestment Deal?

by Zacks Equity Research

Cigna's (CI) Medicare Advantage unit's divestment is expected to fetch around $3-$4 billion.